Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for TRD and Chronic Suicidal Ideation
NCT05220410Phase 2Completed
- Sponsor
- Sheppard Pratt
- Start
- Mar 2022
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of psilocybin in major depressive disorder (MDD) and suicidal ideation, sponsored by Sheppard Pratt. Primary endpoint: Columbia-Suicide Severity Rating Scale at Week 12. Started Mar 2022; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on NCT05220410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220410.